Electrochemical Sensors in Maternal Health: Can We Improve Drug Safety Testing for Pregnant Women?

Ensuring the safety of pharmaceuticals during pregnancy remains a critical challenge in maternal healthcare. Pregnant women are very often excluded from clinical drug trials due to ethical and physiological concerns, resulting in a significant knowledge gap regarding how drugs and environmental chemicals affect fetal development. The LIFESAVER project is working to close this gap by developing in vitro bio-digital twin models that simulate maternal-fetal interactions. One promising technology that could enhance chemical exposure assessment in pregnancy is the use of electrochemical biosensors—a field where i3S (Institute for Research and Innovation in Health, University of Porto, Portugal) has made significant advancements.

A recent publication by i3S, titled “Multi‐Parametric Decision System for Analytical Performance Assessment of Electrochemical (Bio)Sensors” (Advanced Materials Technologies), introduces a multi-parametric framework for assessing the analytical performance of biosensors. This innovative methodology could be highly valuable for LIFESAVER’s drug risk of exposure analysis, ensuring that biosensors used in maternal health studies are both accurate and reliable.

“The integration of advanced multi-parametric electrochemical biosensors into maternal health research represents a major breakthrough in ensuring drug safety during pregnancy. These biosensors, coupled with molecular biomarkers, allow for precise and reproducible monitoring of drug and environmental pollutant exposure by early detection of cellular and tissue responses. By measuring predictive biomarkers of reactivity and transformation to pharmaceutical substances, LIFESAVER can provide critical insights that improve regulatory decision-making and protect fetal development. Our goal is to leverage these technologies to bridge knowledge gaps and develop safer, data-driven healthcare solutions for pregnant women.” – Inês Mendes Pinto, i3S

How Electrochemical Biosensors Can Assess the Impact of Drug and Environmental Pollutant Exposure in Maternal Health

Electrochemical biosensors function by detecting the presence of molecular biomarkers predictive of maternal-fetal health risks, providing rapid and sensitive analysis. The i3S study introduces an advanced decision-support system to optimize the analytical performance of these sensors, ensuring:

Higher sensitivity for detecting low-concentration molecular biomarkers relevant for assessing the impact of exposure to environmental pollutants and drugs.
Improved reproducibility of test results.
Stability in complex biological fluids.

This innovation aligns well with LIFESAVER’s objectives, as one of its key goals is to monitor drug and environmental pollutant transfer across the placental barrier and its corresponding functional impact. By applying the multi-parametric assessment approach developed by i3S, LIFESAVER technology can improve its ability to:

Detect trace levels of molecular biomarkers of early cell/tissue transformation following exposure to drugs and environmental pollutants.
Study the transport dynamics and impact of drugs and environmental pollutants.
Evaluate the cumulative impact of drug and environmental pollutant exposure during pregnancy.

Challenges in Drug Safety Assessments During Pregnancy

One of the biggest hurdles in maternal-fetal pharmacology is the lack of reliable and reproducible testing. Ethical concerns prevent researchers from conducting clinical drug trials on pregnant women, leading to:

A shortage of pharmacokinetic (PK) data for pregnancy-specific drug metabolism.
Uncertain drug safety profiles, leaving physicians to make risk-based assumptions.
Potential fetal exposure to unknown risks, as drug labeling often lacks specific pregnancy-related guidance.

LIFESAVER is addressing this challenge by simulating placental drug transfer using in vitro and in silico models. However, accurate biosensor validation is crucial to ensure these models provide clinically relevant results for maternal-fetal health risk assessment. The i3S multi-parametric framework could enhance the reliability of biosensors used in LIFESAVER’s studies by:

Identifying pre-treatment steps to optimize sensor stability.
Reducing measurement variability in biological samples.
Providing data-driven methodologies for sensor performance optimization.

Sensor Systems for Evaluating Prenatal Drug Exposure Risks

To ensure evidence-based regulatory decisions, it is essential to have reproducible and precise methods for monitoring drug and environmental pollutant exposure and assessing their impact during pregnancy. Sensor systems, as proposed by i3S, integrate:

Electrochemical biosensor performance metrics
Biological sample characteristics
Data-driven decision models to optimize sensor accuracy

By incorporating these approaches, LIFESAVER could enhance its prenatal exposure risk assessment capabilities, leading to:

More reliable predictions of drug transfer across the placenta.
Better-informed risk assessments for pharmaceutical and medical device regulations.
Improved clinical recommendations for pregnant women.

The i3S research on biosensors offers significant potential benefits for the LIFESAVER project, particularly in improving prenatal drug exposure monitoring. By leveraging advanced sensor validation techniques, LIFESAVER can ensure that its in vitro models provide accurate, reproducible, and clinically relevant data to assess fetal chemical exposure risks.

As both initiatives aim to enhance evidence-based policymaking, future collaborations between LIFESAVER and i3S could further strengthen the integration of biosensors into maternal-fetal health research.

For more insights into how LIFESAVER leverages such innovative research to enhance prenatal safety, visit the LIFESAVER project’s website. Here, you can also find updates on other research outputs and initiatives under the LIFESAVER umbrella, driving forward the frontier of maternal and fetal health safety.